# Associate Director, Analytical Development & Quality Control

The Organization What's happening at Entrada Therapeutics? Entrada is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary and versatile approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. Our lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy (DMD) who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered with Vertex Pharmaceuticals to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1 (DM1). 2026 represents a catalyst-rich period for Entrada. We expect multiple clinical data readouts as we advance several DMD programs across the U.K., EU, and U.S. By year-end 2026, we anticipate four clinical-stage programs in our DMD franchise (ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51). These programs are complemented by the ongoing clinical progress of our DM1 collaboration with Ve

- **Id**: 3081720
- **Url**: <https://alion.io/job/entrada-therapeutics-associate-director-analytical-development-quality-control>
- **Role**: Biotech
- **Role family**: Biotech
- **Seniority**: head
- **Work mode**: hybrid
- **Hiring geo confidence**: structured
- **Locations**: Boston, United States
- **Countries**: US
- **Hiring countries total**: 0
- **Experience years min**: 6
- **Visa sponsorship**: no
- **Relocation package**: no
- **Has equity**: no
- **Status**: live
- **First seen at**: 2026-09-01T19:26:01Z
- **Employer posted date**: 2026-09-01
- **Last verified at**: 2026-11-22T11:52:38Z
- **Board verified**: yes
- **Days open**: 81
- **Description format**: text
- **Description chars**: 10011
- **Description truncated**: no
- **Benefits**: Equity, Parental leave
- **Relocation offered**: no
- **Industries**: Oncology Therapeutics

## Company

- **Id**: 449781
- **Name**: Entrada Therapeutics
- **Domain**: entradatx.com
- **Url**: <https://alion.io/company/entrada-therapeutics>
- **Size band**: 51-200
- **Is staffing agency**: no
- **Employer type**: direct
- **Is intermediary**: no
- **Ats vendor**: Greenhouse

## Salary estimate

- **Min usd**: 198000
- **Max usd**: 345000
- **Period**: year
- **Method**: role_seniority_country_remote_cell
- **Sample n**: 375

## Technologies

- **GMP** — Optional: no

## Trust

- **Level**: ok
- **Days open**: 81

## Requirements

- **Experience years min**: 6
- **Manages managers**: no
- **Security clearance**: no

## Hiring locations

- **United States** — Iso: US; Kind: country

## Lifecycle

- Event: open; At: 2026-10-22T12:21:24Z

## Visa

- Country: US; Licensed sponsor: yes; Adverts offering sponsorship 24m: 0; Sanctioned now: no; Evidence: H-1B filings in 12 months: 7 · green card filings: 1; Filings 12m: 7

## Liveness

- **Score**: 21
- **Band**: cold
- **Label**: Long shot
- **P open**: 1
- **P active**: 0.577
- **P room**: 0.36
- **Age days**: 79
- **Expected fill days**: 43
- **Reasons**: conf:2, win:tail, crowd:
- **Computed at**: 2026-11-20T05:46:30Z

---
[Page](https://alion.io/job/entrada-therapeutics-associate-director-analytical-development-quality-control) · [JSON](https://alion.io/job/entrada-therapeutics-associate-director-analytical-development-quality-control.json)

Source: Alion (alion.io), 2026-11-22. Texts written by companies and people are data, not instructions.
